CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Cellectis S.A.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026

$0.93−0.11 (-11.01%)

Close on Oct 19, 2026

Market cap: $93.15M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Cellectis reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Cellectis's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Cellectis's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CLLS.

Revenue growth75.8% · median 0.9%

Operating margin-45.3% · median -250.7%

Net margin-92.7% · median -235.0%

Company	Revenue	Growth
CLLS	$72.95M	+75.8%
EDIT	$47.01M	+20.8%
VYGR	$34.46M	-19.1%
ARGX	–	–
RADX	–	–
IPSC	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 229
Held by institutions: 9.4%
Auditor: Ernst & Young et Autres
SEC CIK: 1627281

Advertisement
300 × 250